menu toggle

Report: Creating a sustainable business model for cell and gene therapies

By AmerisourceBergen

The path to success for new cell and gene therapies (CGTs) is full of challenges. And yet the pressure on therapy manufacturers to deliver results is only growing. To examine how to make development and commercialization of these therapies more sustainable, Economist Impact facilitated a roundtable discussion, supported by AmerisourceBergen, as part of the Cell and Gene Therapy Summit 2023.
Download the Economist report to learn more about what is needed to successfully go to market with these innovative therapies.

We explore:  

  • What makes therapies commercially viable? 
  • How to overcome regulatory challenges 
  • How to make supply chains work for advanced therapies 

Summit Report

The Economist’s inaugural event on CGTs convened leaders and policy decision-makers to accelerate access to transformative products

Access the post event report to discover the key takeaways from over 20 sessions about how healthcare systems and policies need to evolve before therapies can become mainstream.

Connect with our team

A rapidly evolving cell and gene therapy industry requires an equally innovative partner, AmerisourceBergen is committed to delivering solutions that enable this connection.